BeiGene rose 1.42%, with trading value of RMB 1.1255 billion (11.25亿元); net inflow of main funds over the past 3 days was -RMB 132 million (-1.32亿)

On August 26, BeiGene rose 1.42%, with trading volume of RMB 1.1255 billion (11.25亿元), turnover rate of 3.48%, and total market capitalization of RMB 430.298 billion (4302.98亿元).
Anomaly analysis
Innovative drugs + RMB depreciation benefits
1. June 13, 2025, on the Interactive Yi platform: The company is a globally leading oncology innovative therapeutics company. It develops innovative anti-cancer drugs for cancer patients worldwide, improving drug accessibility and affordability.
2. According to the 2024 annual report, the overseas revenue contribution accounted for 62.85%, benefiting from RMB depreciation.
(Disclaimer: The analysis content comes from the internet and does not constitute investment advice. Please make independent judgments based on different market conditions.)
Capital flow analysis
Today’s main net inflow was RMB 52.7716 million, accounting for 0.05%. The industry ranking is 4/157. Main capital has been increasing its holdings for 2 consecutive days. The net inflow for the industry attributable to main capital was -RMB 175 million. There is currently no continuous increase or decrease in positions, and the main capital trend is not obvious.
In the interval, today’s main net inflow was RMB 52.7716 million; over the past 3 days: -RMB 132 million; over the past 5 days: -RMB 77.6347 million; over the past 10 days: -RMB 413 million; over the past 20 days: -RMB 559 million. Main holdings...
Main capital slightly controls the stock; the chip distribution is relatively dispersed. The main capital’s transaction amount is RMB 684 million, accounting for 10.4% of the total transaction amount.
Technical analysis: the average trading cost of the chips is RMB 280.77.
The average trading cost of the chips for this stock is RMB 280.77. Recently, the chips have been reduced, but the pace of reduction has slowed. Currently, the stock price is close to the support level of 277.29. Pay attention to the fact that support is being tested for a rebound; if the price breaks below the support level, it may trigger a new round of downward trend.
Company profile
The information shows that BeiGene Co., Ltd. is located at No. 30 Kejiyuan Road, Zhongguancun Life Sciences Park, Changping District, Beijing. The company was established on October 28, 2010, and listed on December 15, 2021. The company’s principal business covers the research, development, manufacturing, and commercialization of innovative drugs. The revenue composition of its main business is as follows: antitumor drugs 98.81%, and drug collaboration arrangement revenue 1.19%.
BeiGene belongs to the Shenwan industry classification: Medical Biology - Chemical Pharmaceuticals - Chemical Preparations. The concept sectors it belongs to include: innovative drugs, biopharmaceuticals, Healthy China, Shanghai-Hong Kong Stock Connect, and small-cap stocks, among others.
As of March 31, BeiGene’s number of shareholders was 35,400, an increase of 6.50% from the previous period. Shares held per capita were 3,265 shares, a decrease of 6.13% from the previous period. From January to March 2026, BeiGene achieved operating revenue of RMB 10.544 billion, an increase of 31.02% year over year; net profit attributable to the parent company was RMB 1.608 billion, an increase of 1801.30% year over year.
In terms of shareholdings, as of March 31, 2026, among the top ten circulating shareholders of BeiGene, Hong Kong Securities Clearing Company Limited ranked fourth among circulating shareholders, holding 2.9700 million shares, a decrease of 0.4591 million shares from the previous period. Wanjia Preferred (161903) ranked sixth among circulating shareholders, holding 2.0000 million shares; the number of shares held remained unchanged from the previous period. Yongying Medical Innovation Smart Selection Mix A (015915) ranked seventh among circulating shareholders, holding 1.9704 million shares, a decrease of 0.0290 million shares from the previous period. China Europe Healthcare & Health Mix A (003095) ranked eighth among circulating shareholders, holding 1.8127 million shares, a decrease of 2.2996 million shares from the previous period. Industrial and Commercial Bank of China Frontier Healthcare Stock A (001717) ranked tenth among circulating shareholders, holding 1.8000 million shares, a decrease of 0.2000 million shares from the previous period. The Southern CSI 500 ETF (510500) exited the top ten circulating shareholders list.
Statement: The market has risks; investment is需慎重. This article is published based on third-party databases and does not represent opinions of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. In case of discrepancies, please refer to the actual announcements. If you have any questions, please contact biz@staff.sina.com.cn.